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Introduction {#sec1}
============

The discovery that development is not a one-way street but can be reverted by nuclear reprogramming leading to induced pluripotent stem cells (iPSCs) is one of the most promising recent discoveries in translational medicine ([@bib28], [@bib46]). Patient-specific iPSCs not only allow for the modeling of distinct diseases and testing of novel drugs, but also provide unique resources for regenerative medicine ([@bib13]). The possibility to differentiate human iPSCs (hiPSCs) into distinct neuronal cells is already beginning to revolutionize research in the neurodegenerative disease field, indicated by the escalating number of publications focusing on hiPSC-derived neurodegenerative disease models ([@bib33], [@bib44], [@bib17]). Nevertheless, the full potential of hiPSCs is not yet utilized. Using hiPSCs to study the influence of the differentiation state on disease-associated mutations is still in its infancy.

Nuclear reprogramming is initiated by ectopic expression of the four transcription factors OCT4, SOX2, KLF4, and MYC. During this process the epigenetic profile of a somatic cell is reverted in stepwise fashion to the profile of pluripotent stem cells (PSCs), which are able to differentiate into any cell of the three germ layers ([@bib47], [@bib35], [@bib48]). Using patient-derived somatic cells, the initiation of even genetically complex diseases such as Alzheimer's disease ([@bib53]), multiple sclerosis (reviewed in [@bib10]), or early events in tumor initiation ([@bib21]) can be modeled. Therefore, iPSC technology enables investigation not only of early events during the onset of a disease but also the influence of the epigenetic status on the disease. Although previous studies successfully demonstrated reprogramming of cancer cells, reprogramming barriers prevent the successful induction of pluripotency in the majority of tumor cells ([@bib50], [@bib4], [@bib21]).

Here, we applied nuclear reprogramming to different human tumor cell lines. Independent of the mutational status or tumor entity, the constitutive overexpression of the three reprogramming factors OCT4, SOX2, and KLF4 was sufficient to generate iPSC-like tumor cells in the presence of human leukemia inhibitory factor (LIF) that show typical characteristics of murine embryonic stem cells (mESCs). Reprogrammed HT-144 melanoma cells acquired a metastable pluripotent state and could be differentiated into cells of all three germ layers in vivo, and generated neuronal and fibroblast-like cell types in vitro. Notably, reprogrammed cells and their differentiated progeny lost typical melanoma markers and failed to initiate novel melanomas. Moreover, reduced tumorigenicity came together with an increased therapy resistance against the mitogen-activated protein kinase (MAPK) kinase inhibitors vemurafenib and trametinib.

Results {#sec2}
=======

Generation and Characterization of iPCCs {#sec2.1}
----------------------------------------

Previously the induction of a pluripotent state in murine melanoma cells by somatic cell nuclear transfer ([@bib14]) and nuclear reprogramming ([@bib50]) was reported, demonstrating that a reprogrammed melanoma genome can even give rise to a viable organism. Oncogenes represent barriers impeding the reprogramming process ([@bib32]). Accordingly, several studies reported that cancer cell reprogramming is less effective and more time consuming ([@bib50], [@bib31], [@bib26]). To address the question of whether human melanoma cells are amenable to nuclear reprogramming, we used a reverse tetracycline-dependent transactivator (rtTA) and a doxycycline-inducible lentiviral polycistronic vector carrying the reprogramming factors. Since MYC is known to be endogenously expressed in the melanoma cell lines with which we worked, we used OCT4, KLF4, and SOX2 only ([Figure S1](#mmc1){ref-type="supplementary-material"}A) ([@bib22], [@bib42], [@bib3], [@bib55]). Tumor cells carrying the rtTA and the reprogramming factors were subjected to doxycycline-induced expression of the transgenes and manually transferred onto feeder cells ([Figure 1](#fig1){ref-type="fig"}A). Constitutive expression of the reprogramming factors resulted in the appearance of alkaline phosphatase-positive colonies. These iPSC-like tumor cells showed morphological features of mESCs ([Figure 1](#fig1){ref-type="fig"}B) and were similarly resistant to single-cell dissociation without Rho kinase inhibitor (Y-27632), although its addition significantly increased cell survival.

As reactivation of the pluripotency network is a hallmark of successfully reprogrammed cells, we quantified the expression levels of pluripotency markers in reprogrammed melanoma cells compared with iPSCs derived from somatic cells ([Figures 1](#fig1){ref-type="fig"}C and 1D). Independent of the mutational status, all melanoma cell lines subjected to nuclear reprogramming reactivated the endogenous loci of pluripotency factors such as *NANOG*, *SOX2*, *SALL4*, and *TRA-1-60* ([Figures 1](#fig1){ref-type="fig"}C, 1D, [S1](#mmc1){ref-type="supplementary-material"}C, and S1D). Furthermore, we included HeLa cells in the study and demonstrated that human cervical carcinoma cells are also amenable to reprogramming. Since HeLa cells are known to have an amplification of chromosomal region 8q24 which carries the *MYC* locus ([@bib34]) and since there is evidence that the protein is expressed in these cells ([@bib6]), we also reprogrammed them without MYC ([Figure S2](#mmc1){ref-type="supplementary-material"}). We draw the conclusion that tumor cells have the ability to reactivate the pluripotency network independent of their origin and mutational load.

We named these iPSC-like tumor cells induced pluripotent cancer cells (iPCCs). Surprisingly, only a slight increase in OCT4 expression was observed ([Figure 1](#fig1){ref-type="fig"}C), suggesting that tumor cells harbor barriers impeding the reactivation of *OCT4*.

Similar to iPSCs derived from somatic cells ([@bib19], [@bib2], [@bib38]), iPCCs lost markers of their lineage of origin. Accordingly, we observed a downregulation of melanocytic markers such as MITF and TRP1 as well as SOX10 and AP2 compared with the parental melanoma cells ([Figure 1](#fig1){ref-type="fig"}E). Also, iPCCs cluster closer to iPSCs compared with their parental cells of origin and express development-associated TGF-B superfamily members NODAL, LEFTY1, and LEFTY2 as well as the epigenetic modifier DNMTL3 ([Figures 2](#fig2){ref-type="fig"}A--2C).

To assess whether iPCCs acquired a stable pluripotent state, we withdrew doxycycline, thereby stopping reprogramming factor expression. Within 80 hr after withdrawal, NANOG expression levels were reduced by 90% ([Figure 1](#fig1){ref-type="fig"}F), followed by morphological changes and loss of alkaline phosphatase activity ([Figure S3](#mmc1){ref-type="supplementary-material"}). This indicated that the tumor cells could not acquire a stable pluripotent state. To exclude the possibility that the reprogramming process is particularly impeded in tumor cells, we transferred fully reprogrammed melanocyte-derived iPSCs to feeder cells after transgene expression was induced. After two to three passages in the presence of doxycycline on dense feeder cells, the iPSCs formed colonies indistinguishable from the iPCCs ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Together, these data indicate that the metastable pluripotent state is an effect based on the constitutive expression of reprogramming factors and dense feeder cells serving as substrate. Thereby, the partial pluripotent state is not restricted to cancer cells but can also be induced in already fully reprogrammed iPSCs.

To further characterize the cells, we injected HT-144-iPCCs subcutaneously in the flanks of NOD/SCID mice. In all cases tumors developed after 10--12 weeks. Excised tumors stained with H&E demonstrated that the iPCCs differentiated into tissues derived from all three germ layers ([Figure 1](#fig1){ref-type="fig"}G).

A previous publication demonstrated that tumor-iPSCs resemble early stages of tumor development in vivo ([@bib21]). Hence, we analyzed the expression of typical melanoma and standard tumor markers in tumors derived from iPCCs and the parental melanoma cells ([Figures 3](#fig3){ref-type="fig"}A--3D). Parental tumor lines generated homogeneous S100B-positive melanomas with high expression of the proliferation marker Ki67, and were negative for epithelial cytokeratins. In contrast, iPCC-derived teratomas showed multiple areas of differentiated foci that were architecturally organized and contained irregularly shaped cells with enlarged cytoplasm. In addition, formation of gland-like structures was observed in most of the tumors that developed from iPCCs. Independent of the mutational status, iPCC-derived tumors rarely generated any S100B-positive melanoma-like structures. Furthermore, we observed epithelial structures in iPCC-derived tumors. According to the heterogeneous pattern of cellular differentiations, the proliferation marker Ki67 was present in distinct tissue structures but was rarely expressed in the tumor mass.

iPCCs Can Be Terminally Differentiated into Different Cell Lineages {#sec2.2}
-------------------------------------------------------------------

Next, we assessed whether iPCCs can be terminally differentiated in vitro into cell lineages different from that of the parental cells. We applied a previously published neuronal differentiation strategy based on dual SMAD inhibition using small molecules inhibiting SMAD and GSK3β signaling ([Figure 4](#fig4){ref-type="fig"}A) in combination with a low dose of Noggin and the bone morphogenetic protein (BMP) inhibitor LDN-193189 ([@bib8], [@bib25]). Within 3 days after induction of neuronal differentiation, the first axon-like structures appeared and elongated with continued differentiation ([Figure 4](#fig4){ref-type="fig"}B). In accordance with the differentiation, pluripotency markers NANOG and OCT4 were downregulated. Nevertheless, expression levels of both transcription factors were clearly higher than in the parental cell line, suggesting that the differentiation was not yet complete, although early neuronal markers such as microtubule-associated protein 2 (MAP2) and PAX6 were increased. After 20--50 days, the late post-mitotic neuronal marker RBFOX3 was significantly upregulated in HT-144-derived neuronal-like cells while parental HT-144 cells were negative for all neuronal markers ([Figures 4](#fig4){ref-type="fig"}C and 4D). Immunofluorescence staining of TUJ1 in neuronal differentiated cells derived from HT-144-iPCCs constitutively expressing GFP confirmed the successful neuronal differentiation ([Figure 4](#fig4){ref-type="fig"}E).

Since iPCC-derived neuronal cells became post-mitotic, we applied a differentiation protocol that guided cells toward mesodermal lineage by stimulation with epidermal growth factor (EGF), insulin, and at later stages with additional BMP-4 ([Figure 5](#fig5){ref-type="fig"}A). Loss of melanoma and pluripotency markers indicated a non-melanocytic cell identity ([Figure 5](#fig5){ref-type="fig"}B). Due to the formation of spindle-like cells resembling normal human fibroblasts (NHFs) ([Figure 5](#fig5){ref-type="fig"}C), we named the cells HT-144-derived fibroblast-like cells (HT-144-dFLCs). These cells were clonally selected from two independent differentiations (HT-144-dFLCs-I and -II) and could be cultured for more than 40 passages.

The Global Methylation Profile of iPCCs Resembles the Profiles of PSCs {#sec2.3}
----------------------------------------------------------------------

To further assess the epigenetic similarities between the different cell types, we performed a global methylation analysis and grouped the cells according to their methylation status ([Figures 5](#fig5){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}). Cells with a similar methylation profile clustered together in a multidimensional scale. As expected, the melanoma cell lines formed one cluster, as well as iPCCs and differentiated progeny. Using published methylation data from human embryonic stem cells (hESCs) and hiPSCs, we showed that the iPCCs moved toward stable PSCs but formed a separate cluster, indicating that the majority of methylation sites showed a similar profile to that of the PSCs. In contrast, the methylation profile of HT-144-dFLCs was distinct from the profile of NHFs.

iPCC-Derived Fibroblasts Show No Tumorigenic Potential {#sec2.4}
------------------------------------------------------

Previous publications demonstrated that reprogrammed tumor cells can acquire a non-tumorigenic phenotype ([@bib50], [@bib45], [@bib12]). Nevertheless, so far there is no evidence of how epigenetic modifications take shape in cells harboring constitutively active oncogenes. Therefore, we investigated the tumor-initiating potential of the parental cell line and HT-144-dFLC-II by subcutaneous injection in NSG mice. We observed no tumor formation in any of the HT-144-dFLC-II injected animals over a time period of 18 weeks. In contrast, all mice injected with the parental cells were euthanized after 5.5 weeks because of the formation of large tumors ([Figure 5](#fig5){ref-type="fig"}E).

iPCCs and iPCC-Derived Fibroblasts Lose Their Oncogene Addiction {#sec2.5}
----------------------------------------------------------------

It has recently been demonstrated that malignant leukemia cells lose their oncogene dependence by nuclear reprogramming into iPSCs ([@bib7]). Due to the activating V600E mutation in HT-144 cells as a key driver of melanoma initiation and progression, we focused on MAPK signaling before and after the reprogramming process. Previous data demonstrated that the reprogramming process selects for cells harboring a low mutational load ([@bib26]). Therefore, as a first step we confirmed that all HT-144-derived cells harbored the *BRAF*^*V600E*^ mutation ([Figure 6](#fig6){ref-type="fig"}A) using *BRAF*^*V600E*^-specific primers. Moreover, we found that the *BRAF*^*V600E*^-mutated HT-144, HT-144-iPCCs, and HT-144-dFLCs showed a methylation profile similar to that of the *BRAF* locus ([Figure 6](#fig6){ref-type="fig"}B). In line with this, we found high levels of phosphorylated ERK in all three cell types ([Figure 6](#fig6){ref-type="fig"}C). These results indicate that reprogramming of *BRAF*^*V600E*^-positive melanoma cells and in vitro differentiation of the iPCCs lead neither to the loss of the oncogene mutation nor to an epigenetic remodeling process that silences the gene. Fluorescence in situ hybridization (FISH) analysis also shows no gain or loss of gene copy numbers related to genes of the BRAF-MEK-ERK signaling pathway ([Figure 6](#fig6){ref-type="fig"}D). However, in vivo differentiation of HT-144-iPCCs generated tumors containing structures without ERK activity ([Figure 6](#fig6){ref-type="fig"}E), suggesting that MAPK activity is restricted to cells of a specific tissue type.

Next, we investigated the response of reprogrammed melanoma cells and differentiated daughter cells to targeted melanoma therapies. Parental melanoma cells and the reprogrammed iPCCs were treated with 1 μM of the MEK inhibitor trametinib and with the oncogene-specific BRAF inhibitor vemurafenib. Treatment with trametinib reduced cell proliferation in all melanoma cell lines and resulted in the appearance of floating, dead cells. In accordance with their mutational status, HT-144 cells were sensitive to vemurafenib treatment, unlike the *BRAF* wild-type cell lines Mewo and SKMEL147. Compared with the parental cell lines, iPCCs showed increased therapy resistance against MAPK inhibition without affecting the expression of the pluripotency marker alkaline phosphatase ([Figure 6](#fig6){ref-type="fig"}F).

To exclude that the ectopic expression of the pluripotency factors facilitates the therapy resistance, we investigated the therapy response in HT-144-dFLCs. Concentrations of 1,000 nM trametinib and 100 nM vemurafenib, which effectively killed HT-144 melanoma cells, showed no significant effect on HT-144-dFLCs ([Figures 6](#fig6){ref-type="fig"}G and [S5](#mmc1){ref-type="supplementary-material"}). These data suggest that despite the presence of the mutated oncogene and its signaling activity, epigenetic modifications can facilitate a loss of oncogene addiction, which in turn results in resistance to targeted therapies.

Discussion {#sec3}
==========

Here, we present a method to induce a pluripotent-like state even in tumor cells with a high mutational load. Melanoma cells harboring *BRAF*^*V600E*^ or *NRAS* mutations were amenable to reprogramming similarly to wild-type cells. In contrast to the "classical" reprogramming protocol, we constitutively overexpressed OCT4, SOX2, and KLF4 and cultivated the cells similar to mESCs in the presence of human LIF on dense feeder cells. Previous studies in fibroblasts described similar murine-like ESCs upon ectopic expression of OCT4, SOX2, KLF4, MYC, and NANOG when supplemented with LIF. Like our iPCCs, these cells formed tightly packed colonies and could not stabilize the maintenance of the pluripotent state ([@bib5]). In contrast to our study, those cells did not reactivate the expression of endogenous pluripotency markers. Recently it was demonstrated that ectopic expression of reprogramming factors can generate an alternative NANOG-positive cell state. Although these so-called F-class cells share many features with our iPCCs in terms of gene expression and transgene dependence, F-class cells did not undergo mesenchymal-to-epithelial transition (MET) ([@bib49]), an early event during the reprogramming progress ([@bib30], [@bib40]). On a molecular level, the successfully completed MET manifests itself by an upregulation of E-cadherin ([@bib9]). This indicates that iPSC-like tumor cells generated in this study proceeded further in the reprogramming process than the F-class cells ([Figure 2](#fig2){ref-type="fig"}D). Similarly to early reports, we found that endogenous expression of reprogramming genes can compensate for ectopic expression ([@bib50], [@bib36]). This allowed us to reprogram the melanoma cells with OCT4, SOX2, and KLF4 only, without using the oncoprotein MYC.

A defined pattern of epigenetic signatures determines a cellular fate. Nuclear reprogramming allows us to reset a cell's specific profile of epigenetic marks to direct its cell fate using differentiation protocols. Resetting the epigenetic profile of melanoma cells into a pluripotent-like state facilitated the differentiation of melanoma iPCCs into terminally differentiated cells. Although all melanoma cell lines investigated in this study were sensitive to MEK inhibition and in the case of HT-144 additionally to BRAF inhibition, their respective melanoma iPCCs as well as iPCC-derived in vitro differentiations lost their oncogene dependence, indicated by the resistance to targeted therapy. The same phenomenon was observed in reprogrammed human myeloid leukemia cells, which lost their dependence on the *BCR-ABL* oncogene upon reprogramming or after terminal differentiation into non-hematopoietic lineages ([@bib7], [@bib23]).

Reprogramming toward pluripotency induces a stepwise increase in the developmental potential. This allows tumor cells to acquire a terminal differentiation other than its origin ([@bib54]). Fully reprogrammed murine R545 melanoma cells even gained the potential to give rise to a viable mouse ([@bib50]). Accordingly, we observed that *BRAF* mutant melanoma iPCCs can be differentiated into neurons and fibroblast-like cells in vitro. In vivo, the majority of iPCC-derived tumors did not contain melanoma cells. In contrast to our results, other studies showed that reprogrammed pluripotent cells tend to differentiate into the cell type of their origin. Reprogrammed pancreatic cancer cells predominately differentiate into pancreatic tissue, recapitulating early and late events of carcinoma development ([@bib21]). This phenomenon is based on epigenetically anchored marks that generate an epigenetic memory ([@bib2], [@bib20]). Here, we did not observe that the melanoma-derived iPCCs preferentially differentiate into a melanocytic lineage in vivo. Furthermore, no differences between Mewo-iPCCs, lacking *BRAF* or *NRAS* mutations, and other melanoma iPCCs, harboring mutations in members of the MAPK signaling, were observed. These results suggest that mutations of components of the MAPK pathway do not interfere with the epigenetic memory and hence do not influence differentiation toward the melanocytic lineage.

One major drawback of current melanoma therapy is the development of resistance mechanisms against novel therapeutics targeting the MAPK members RAF or MEK. Upon MAPK inhibition, additionally acquired mutations reactivate the MAPK pathway by gain of *RAF* gene copy numbers ([@bib43], [@bib51]), and mutations in *RAS* ([@bib39]) or receptor tyrosine kinases ([@bib37]), leading to therapy resistance. However, recent data revealed that a considerable amount of resistant melanomas show no genomic but rather transcriptomic alterations as drivers of therapy resistance caused by epigenetic modifications ([@bib16]). Here, we demonstrated that epigenetic modifications in melanoma cells induced by nuclear reprogramming can lead to therapy resistance against BRAF and MEK inhibitors. This supports the notion that therapy response is linked to the cellular differentiation state. A dedifferentiation of melanoma cells was already linked to the resistance to adoptive T cell therapy ([@bib27]), indicating a clinical relevance of melanoma cell state for therapy outcome.

Global epigenetic remodeling processes are well-known hallmarks of tumor development and also play an import role in melanomagenesis (reviewed in [@bib29]). Nevertheless, the vast majority of melanomas shares common mutational events. In most cases, mutations leading to constitutively active RAS or RAF molecules combined with loss of tumor suppressors are key drivers of melanomagenesis ([@bib15]). Thus, nuclear reprogramming provides a tool to study the influence of a tumor genome on tumorigenesis in the context of specific cellular differentiation states. In this study, melanoma cells harboring *BRAF* mutations lost their tumor-initiating potential during the reprogramming process. Furthermore, dedifferentiation of melanoma cells is assumed to enhance their malignant potential ([@bib27]). Expression of single stem cell factors such as OCT4 or SOX2 increases melanoma stem cell properties, leading to a more aggressive tumor phenotype ([@bib24], [@bib41], [@bib52]). In contrast, the simultaneous expression of three pluripotency markers leading to a semi-stable pluripotent state reduces the tumor-initiating potential.

In the majority of melanomas, oncogenic mutations of genes of the MAPK pathway drive tumor development. The well-known *BRAF*^*V600E*^ mutation is responsible for constitutively active BRAF leading to hyperactive MAPK signaling. Targeting the tumor-specific mutation with small molecules provided a breakthrough in melanoma therapy, although resistance mechanisms leading to disease relapse rapidly damped expectations. We demonstrated that melanoma cells can acquire a metastable pluripotent state independent of *BRAF* or *NRAS* mutations. The cells reactivate expression of endogenous pluripotency markers and show further characteristics of PSCs, such as the potential to generate teratomas after subcutaneous injection into the flanks of immunocompromised mice. Interestingly, OCT4 expression was not upregulated, which might prevent the acquisition of a stable pluripotent state. In accordance, reprogrammed tumor cells remained dependent on the ectopic overexpression of the reprogramming factors.

Here, we demonstrated that a melanoma genome could be reprogrammed into a metastable mESC-like state of pluripotency. We could also show that subsequent differentiation of these pluripotent cells toward the mesodermal lineage was consistent with significantly impaired tumorigenicity. Therefore, we demonstrated a direct correlation between the tumorigenic potential of a cancer cell and its differentiation status.

Experimental Procedures {#sec4}
=======================

Ethics Statement {#sec4.1}
----------------

Experiments with primary human material were conducted with patients' informed consent and were approved by the Medical Ethics Committee of the Medical Faculty Mannheim, Heidelberg University. Animal experiments were approved by the Animal Experiments Committee.

Cell Culture of Tumor Cells and Murine Embryonic Fibroblasts {#sec4.2}
------------------------------------------------------------

The *BRAF*^*V600E*^ mutant melanoma cell lines HT-144 and A375, the *BRAF*^*V600D*^ mutant cell line WM266.4, the *NRAS* mutant cell line SK-MEL147, the *BRAF* and *NRAS* wild-type cell line Mewo, and murine embryonic fibroblasts were cultivated in DMEM (Gibco Life Technologies) with 4,500 mg/L glucose and 4 mM L-alanyl-L-glutamine supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Biochrom), 1% (v/v) 100× non-essential amino acids (NEAA; Sigma-Aldrich), 100 units/mL penicillin (Sigma-Aldrich), 100 μg/mL streptomycin (Sigma-Aldrich), and 0.1 mM 2-mercaptoethanol (Gibco Life Technologies). When 80% confluence was reached, cells were passaged using a 21-mM trypsin solution (Sigma-Aldrich). All cells were grown in a humidified atmosphere at 37°C and 5% CO~2~. Trametinib and vemurafenib (both Selleck Chemicals) were dissolved in DMSO (Carl Roth) and administered as indicated.

Generation of iPSCs and iPCCs {#sec4.3}
-----------------------------

For reprogramming of human tumor cells, fibroblasts and melanocytes (10^5^ cells per cm^2^) were seeded on gelatin-coated plates and transduced with FUdeltaGW-rtTA-zeocin. Cells were selected with 100 μg/mL zeocin (Invivogen) in complete medium and then co-infected with tetO-hSTEMCCA-puro-loxP encoding for OCT4, SOX2, KLF4, and a puromycin resistance gene or alternatively with tetO-hSTEMCCA-loxP encoding for OCT4, SOX2, KLF4, and MYC. The next day, superinfection was performed to reach higher efficiencies. All transductions were conducted for 24 hr at 37°C in DMEM supplemented with 10 μg/mL polybrene (Sigma-Aldrich). Twenty-four hours after the last infection, 10^5^ cells in complete medium were plated onto 6-well plates coated with gelatin. After the cells attached, doxycycline (Sigma-Aldrich) was added to the medium to induce transgene expression. From here on the medium was changed every second day. After 30--40 days the first colony-forming cells originated. To create reprogrammed clones derived from single cells, we manually transferred individual colonies onto fresh feeder cells in DMEM/F12 (Gibco Life Technologies) with 20% (v/v) knockout serum replacement (KOSR) (Gibco Life Technologies), 2 mM L-glutamine (Sigma-Aldrich), 1% (v/v) NEAA, 100 units/mL penicillin, 100 μg/mL streptomycin, 0.1 mM 2-mercaptoethanol, and 1 μg/mL doxycycline, supplemented with 10 ng/mL human LIF (Sigma-Aldrich).

Human iPSC Culture {#sec4.4}
------------------

Stable clones of human iPSCs were cultivated under xeno-free cell-culture conditions using a synthetic surface matrix. One day in advance, 6-well plates were coated with Matrigel (Stemgent) for 1 hr at room temperature and stored at 4°C. Human iPSCs were washed and undifferentiated parts were manually dissociated into cell clusters of 50--100 cells. These small cell aggregates were transferred to Matrigel-coated plates in mTeSR1 medium (STEMCELL Technologies) containing 20% (v/v) mTeSR1 supplements of BSA, recombinant human basic fibroblast growth factor (bFGF), recombinant human TGF-B, lithium chloride, pipecolic acid, and G-aminobutyric acid (STEMCELL Technologies). Every other day medium was changed and the differentiated parts manually removed. Alternatively, human iPSCs were cultivated on feeder cells in human ES medium, which consists of DMEM/F12 supplemented with 20% (v/v) KOSR, 2 mM L-glutamine, 1% (v/v) NEAA, 100 units/mL penicillin, 100 μg/mL streptomycin, 0.1 mM 2-mercaptoethanol, and 10 ng/mL bFGF (Promokine).

Culture of Human iPCCs {#sec4.5}
----------------------

Growth-arrested feeder cells were plated on gelatin-coated 6-well plates in complete medium and incubated for 2 days to ensure proper attachment and spread. iPCCs were then transferred onto feeder cells and medium was changed to DMEM/F12 with 20% (v/v) KOSR, 2 mM L-glutamine, 1% (v/v) NEAA, 100 units/mL penicillin, 100 μg/mL streptomycin, 0.1 mM 2-mercaptoethanol, and 1 μg/mL doxycycline, supplemented with 10 ng/mL human LIF. For passaging, cells were harvested every 4--7 days using trypsin and replated at 1:30 to 1:100 dilutions in medium containing 10 μM ROCK inhibitor (Y-27632, Stemgent). For separation of iPCCs from feeder cells by preplating, cells were harvested using trypsin, dissociated into single cells, washed, and resuspended in medium containing ROCK inhibitor. The cell suspension was then transferred onto gelatin-coated tissue culture plates and incubated for 2 hr at 37°C. Undifferentiated cells floating in the supernatant were collected and prepared for further experiments.

Fibroblast Differentiation {#sec4.6}
--------------------------

For the differentiation into fibroblast-like cells, HT-144-iPCCs were seeded onto 80% confluent mitotically inactivated feeder cells in naive human ES medium with 10 μM ROCK inhibitor and 1 μg/mL doxycycline, and cultivated for 2--5 days until small colonies were formed. Different protocols were followed to establish the clones I--III. Clone I was generated by changing the medium to DMEM/F12 1:1 with Neurobasal medium (Gibco Life Technologies) containing 1% B27 (Gibco Life Technologies) and 0.5% (v/v) N2 supplement (Gibco Life Technologies) for 3 days. The medium was then also switched to complete medium with 20% (v/v) fetal calf serum (FCS). For clone II, iPCC colonies were cultivated in DMEM/F12 3:1 supplemented with 10% (v/v) FCS, 0.18 mM adenine (Sigma-Aldrich), 0.5 μg/mL hydrocortisone (Sigma-Aldrich), 100 pM cholera toxin (Sigma-Aldrich), 10 ng/mL EGF (Gibco Life Technologies), and 5 μg/mL insulin (Sigma-Aldrich) for 10 days and supplemented on days 4--10 with 0.5 nM BMP-4 (Promokine). Afterward, fibroblast-like cells were split and maintained in T75 cell-culture flasks with complete medium.

Neuronal Differentiation {#sec4.7}
------------------------

For neuronal induction, 2 × 10^4^ cells per cm^2^ were seeded on Matrigel-coated dishes in DMEM/F12 with 20% (v/v) KOSR, 2 mM L-glutamine, 1% (v/v) NEAA, 100 units/mL penicillin, 100 μg/mL streptomycin, 0.1 mM 2-mercaptoethanol, and 1 μg/mL doxycycline, supplemented with 10 ng/mL human LIF and 10 μM ROCK inhibitor. When small colonies of five to ten cells appeared, medium was changed to DMEM/F12 and Neurobasal mixed at a 1:1 ratio with 1% (v/v) B27 and 0.5% (v/v) N2, 100 ng/mL Noggin (R&D Systems), 0.5 μM LDN-193189 (Stemgent), 10 μM SB-431542 (Tocris), 2 μM CHIR-99021 (Selleckchem), 10 μM forskolin (Tocris), and 10 ng/mL bFGF for 3--10 days. Then, cells were cultivated for an additional 5--10 days without small compound inhibitors but in the presence of 10 ng/mL bFGF.

Methylation Array Analysis {#sec4.8}
--------------------------

Genome-wide methylation analysis using Illumina Infinium HumanMethylation450 BeadChips according to the manufacturer's instructions was performed at the German Cancer Research Center (DKFZ) Genomics and Proteomics Core Facility. The data discussed in this publication have been deposited in the NCBI GEO ([@bib11]) and are accessible through series accession number GEO: [GSE95816](ncbi-geo:GSE95816){#intref0010} (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE95816>). Raw-intensity data files of the following publicly available HumanMethylation450 samples from the ENCODE project ([@bib18]) were downloaded from <http://www.encodeproject.org>: ENCBS111ENC. The software RnBeads ([@bib1]) was used for quality assessment, normalization, dimension reduction, and other analyses of the combined dataset.

Cell Viability Assay {#sec4.9}
--------------------

Cell viability was analyzed using the alamarBlue Cell viability assay (Thermo Fisher Scientific). Cells were plated in black 96-well plates in phenol-free DMEM (Gibco Life Technologies). After 24 hr at 37°C, 100 μL of medium was added and supplemented with DMSO or inhibitors for final concentrations ranging from 1 nM to 1 μM. At indicated time points 1/10 alamarBlue was added followed by fluorescence measurement 2--4 hr later at 37°C using a SpectraMax M5 microplate reader with an excitation wavelength of 540 nm and an emission wavelength of 590 nm. Cell viability was calculated from the resulting change in fluorescence intensity normalized to cells exposed to vehicle only.

Animal Experiments {#sec4.10}
------------------

For analysis of tumor initiation and in vivo differentiation potential, 1 × 10^6^ cells were resuspended in 50% Matrigel and subcutaneously injected in either NOD/SCID mice or NSG mice according to the German Animal Protection Law. Mice were euthanized and developing tumors were isolated when reaching the size of 1 cm in diameter.
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![Generation and Characterization of Metastable Reprogrammed Melanoma Cells\
(A) Scheme for tumor cell reprogramming.\
(B) Reprogrammed tumor cells form ESC-like alkaline phosphatase-positive colonies on feeder cells.\
(C) qPCR measurement shows reactivation of the endogenous loci of the pluripotency markers *NANOG*, *SOX2*, and *SALL4* but only mild increase in endogenous *OCT4* expression. *GAPDH* was used as endogenous control and hiPSCs as reference sample. Indicated is the mean ± SD. p Values were calculated by two-tailed, unpaired sample t test of technical triplicates in two clones of SKMEL147-and Mewo-iPCCs and in three independent experiments of HT-144-iPCCs. Asterisk indicates t test p value of ≤0.05 in comparison with the respective reference (^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, ^∗∗∗^p ≤ 0.005).\
(D) Immunofluorescence staining of NANOG and TRA-1-60 in the parental melanoma cells (I) and melanoma iPCCs (II). DAPI was used for nuclear counterstaining.\
(E) qPCR analysis reveals loss of melanocytic markers in iPCCs compared with their parental melanoma cell lines. Gene expression levels were normalized to *GAPDH*. Error bars indicate 95% confidence intervals. p Values were calculated from three independent experiments by two-tailed, unpaired sample t test. Asterisk indicates t test p value of ≤0.05 in comparison with the respective reference (^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, ^∗∗∗^p ≤ 0.005).\
(F) *NANOG* expression analyzed by qPCR in HT-144-iPCCs at indicated time points after doxycycline withdrawal compared with the parental HT-144. Nanog expression was normalized to internal GAPDH. Error bars indicate 95% confidence intervals. Dotted line, normalization to day 0.\
(G) Metastable melanoma iPCCs form teratomas in vivo showing tissue structures of mesodermal (I), ectodermal (II), and endodermal (III) origin. Paraffin-embedded tumor slices were stained with H&E.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Characterization of Melanoma iPCCs\
(A) Heatmap and dendrogram generated by unsupervised hierarchical clustering of differentially regulated genes (empirical Bayes moderated t test, p \< 0.05) in HT-144, HT-144-iPCCs, and hiPSCs. Red indicates increased expression and green decreased expression relative to the control.\
(B--D) qPCR analysis of melanoma iPCCs compared with their reprogrammed progeny. iPSCs were used as reference sample. Data were obtained from three independent experiments. (B) Expression analysis of development-associated TGF-B superfamily members *NODAL*, *LEFTY1*, and *LEFTY2*. (C) Expression analysis of the epigenetic modifier *DNMTL3*. (D) Expression analysis of the MET marker E-cadherin. *GAPDH* was used as endogenous control and hiPSCs as reference sample. Error bars indicate 95% confidence intervals. Indicated is the mean + SD. p Values were calculated by two-tailed, unpaired sample t test. Asterisk indicates t test p value of ≤0.05 in comparison with the respective reference (^∗∗∗^p ≤ 0.005).](gr2){#fig2}

![Reduced Tumor Marker Expression in Reprogrammed Melanoma Cells\
(A) Histological staining for the melanoma marker S100B in melanomas derived from HT-144, Mewo, and SKMEL147 cells and their respective reprogrammed progeny.\
(B) In contrast to melanomas, S100B expression is restricted to neuronal-like cells in HT-144-iPCC-derived teratomas (indicated by arrows).\
(C) Histological staining for epithelial cytokeratins (PanCK) in HT-144-iPCC-derived tumors and melanomas derived from the parental HT-144 cells.\
(D) Histological analysis of the expression of the proliferation marker KI67 in melanomas derived from HT-144, Mewo, and SKMEL147 cells and their respective reprogrammed progeny.](gr3){#fig3}

![HT-144-iPCCs Efficiently Differentiate into Neuronal Cells\
(A) Schematic illustration of the neuronal differentiation protocol.\
(B) Morphology of HT-144-iPCCs subjected to neuronal induction at indicated time points.\
(C and D) qPCR analysis of pluripotency marker (C) as well as early and late neuronal marker expression (D). Data were pooled from three independent experiments. *NANOG* and *OCT4* were normalized to hiPSCs. The neuronal markers *MAP2*, *PAX6*, and *RBFOX3* were normalized to hiPSC-derived neuronal cells. *GAPDH* served as internal control. Error bars indicate 95% confidence intervals. p Values were calculated by two-tailed, unpaired sample t test. Asterisk indicates t test p value of ≤0.05 in comparison with the respective reference (^∗∗∗^p ≤ 0.005).\
(E) Immunofluorescence staining of B3-tubulin in HT-144-iPCCs (I) and iPCC-derived neuronal cells (II). iPCCs used for the staining constitutively express GFP.](gr4){#fig4}

![Melanoma iPCCs Gain the Potential to Terminally Differentiate into Non-tumorigenic Cells\
(A) Schematic protocol for the differentiation of iPCC-derived fibroblast-like cells.\
(B) qPCR analysis of *NANOG* and *MITF* expression in HT-144, reprogrammed HT-144-iPCCs, and iPCC-derived fibroblast-like cells (HT-144-dFLC-I). *GAPDH* served as endogenous control. Error bars indicate 95% confidence intervals. p Values were calculated from three independent experiments by two-tailed, unpaired sample t test. Asterisk indicates t test p value of ≤0.05 in comparison with the respective reference (^∗^p ≤ 0.05, ^∗∗∗^p ≤ 0.005).\
(C) Morphological comparison of the parental cell line HT-144 and fibroblast-like cells from two differentiations (HT-144-dFLC) with NHFs.\
(D) Global methylation profiles of A375 and HT-144 compared with the profiles of their respective iPCCs and HT-144-iPCC-derived fibroblast-like cells from three independent differentiations were used for a multidimensional scaling. Human fibroblasts (pink squares represent preparations from two different individuals), hiPSCs, and a publicly available dataset of hESCs were added as controls.\
(E) Survival of mice after subcutaneous injection of 1 × 10^6^ parental HT-144 melanoma cells or HT-144-iPCC-derived fibroblasts, respectively. Parental HT-144 melanoma cells gave rise to tumors in all five cases while no tumor growth was observed in five mice injected with HT-144-dFLC-II even after 20 weeks (one mouse was euthanized for other reasons).](gr5){#fig5}

![Epigenetic Modifications Induced by Nuclear Reprogramming Lead to Therapy Resistance against MAPK Inhibitors in Melanoma Cells\
(A) Oncogene-specific PCR analysis of *BRAF*^*V600E*^ in the parental HT-144 cells, HT-144-iPCCs, and iPCC-derived fibroblast-like cells. Human fibroblasts were used as a negative control.\
(B) Methylation analysis of the *BRAF* locus in HT-144, HT-144-iPCCs, and HT-144-dFLCs.\
(C) ERK activity in reprogrammed HT-144-iPCCs and fibroblast-like cells compared with the parental cell line determined by western blot analysis of phosphorylated ERK. GAPDH was used as an internal reference control for semi-quantitative protein analysis.\
(D) FISH of HT144 and HT144-iPCCs shows no gain or loss of gene copy numbers related to genes of the BRAF-MEK-ERK signaling pathway such as *BRAF* (shown are nuclei with signals for the *BRAF* gene locus \[red\] and a centromeric reference probe \[green\]).\
(E) HT-144-iPCCs give rise to tumors with reduced ERK activity in distinct differentiated structures. Histological staining of total ERK (tERK) and phosphorylated ERK (pERK) in HT-144-iPCC-derived tumors.\
(F) Treatment of parental melanoma cells and their reprogrammed counterparts with the MEK inhibitor trametinib and the BRAF^V600E^-specific inhibitor vemurafenib.\
(G) Therapy response of MAPK inhibitor-treated HT-144 and two fibroblast-like in vitro differentiations. Cells were incubated with 1,000 nM trametinib and 100 nM vemurafenib and analyzed for their metabolic activity at indicated time points.\
See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}
